Downregulation of lncRNA-ATB correlates with clinical progression and unfavorable prognosis in pancreatic cancer

Tumor Biology

Volumn 37, Issue 3, 2016, Pages 3933-3938

  Qu, Shibin ^a   Yang, Xisheng ^a   Song, Wenjie ^a   Sun, Wei ^a   Li, Xiaolei ^a   Wang, Jianlin ^a   Zhong, Yue ^a   Shang, Runze ^a   Ruan, Bai ^a   Zhang, Zhuochao ^a   Zhang, Xuan ^a   Li, Haimin ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

lncRNA ATB; Long noncoding RNA; Pancreatic cancer; Prognosis

Indexed keywords

LONG UNTRANSLATED RNA; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER; LONG NONCODLNG RNA ATB, HUMAN;

ADULT; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CARCINOGENESIS; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATIONAL STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TUMOR INVASION; CELL LINE; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICS AND NUMERICAL DATA; TUMOR CELL LINE;

CELL LINE; CELL LINE, TUMOR; DISEASE PROGRESSION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PANCREATIC NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, LONG NONCODING; TRANSFORMING GROWTH FACTOR BETA;

EID: 84944705267     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-4252-y     Document Type: Article

References (28)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29. doi:10.3322/caac.21254.
2. Ryan DP, Hong TS, Bardeesy N. N Engl J Med. 2014;371(22):2140–1. doi:10.1056/NEJMc1412266.
3. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378(9791):607–20. doi:10.1016/S0140-6736(10)62307-0.
4. Hartwig W, Werner J, Jäger D, Debus J, Büchler MW. Improvement of surgical results for pancreatic cancer. Lancet Oncol. 2013;14(11):e476–85. doi:10.1016/S1470-2045(13)70172-4.
5. Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell. 2009;136(4):629–41. doi:10.1016/j.cell.2009.02.006.
6. Shi X, Sun M, Liu H, Yao Y, Song Y. Long non-coding RNAs: a new frontier in the study of human diseases. Cancer Lett. 2013;339(2):159–66. doi:10.1016/j.canlet.2013.06.013.
7. Xu SP, Zhang JF, Sui SY, Bai NX, Gao S, Zhang GW, et al. Down regulation of the long noncoding RNA EGOT correlates with malignant status and poor prognosis in breast cancer. Tumour Biol. 2015. doi:10.1007/s13277-015-3746-y.
8. Huarte M, Rinn JL. Large non-coding RNAs: missing links in cancer? Hum Mol Genet. 2010;19(R2):R152–61. doi:10.1093/hmg/ddq353.
9. Li J, Liu D, Hua R, Zhang J, Liu W, Huo Y, et al. Long non-coding RNAs expressed in pancreatic ductal adenocarcinoma and lncRNA BC008363 an independent prognostic factor in PDAC. Pancreatology. 2014;14(5):385–90. doi:10.1016/j.pan.2014.07.013.
10. Sun YW, Chen YF, Li J, Huo YM, Liu DJ, Hua R, et al. A novel long non-coding RNA ENST00000480739 suppresses tumour cell invasion by regulating OS-9 and HIF-1α in pancreatic ductal adenocarcinoma. Br J Cancer. 2014;111(11):2131–41. doi:10.1038/bjc.2014.520.
11. Ma C, Nong K, Zhu H, Wang W, Huang X, Yuan Z, et al. H19 promotes pancreatic cancer metastasis by derepressing let-7’s suppression on its target HMGA2-mediated EMT. Tumour Biol. 2014;35(9):9163–9. doi:10.1007/s13277-014-2185-5.
12. Kim K, Jutooru I, Chadalapaka G, Johnson G, Frank J, Burghardt R, et al. HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer. Oncogene. 2013;32(13):1616–25. doi:10.1038/onc.2012.193.
13. Jiao F, Hu H, Yuan C, Wang L, Jiang W, Jin Z, et al. Elevated expression level of long noncoding RNA MALAT-1 facilitates cell growth, migration and invasion in pancreatic cancer. Oncol Rep. 2014;32(6):2485–92. doi:10.3892/or.2014.3518.
14. Pang EJ, Yang R, Fu XB, Liu YF. Overexpression of long non-coding RNA MALAT1 is correlated with clinical progression and unfavorable prognosis in pancreatic cancer. Tumour Biol. 2015;36(4):2403–7. doi:10.1007/s13277-014-2850-8.
15. Yuan JH, Yang F, Wang F, Ma JZ, Guo YJ, Tao QF, et al. A long noncoding RNA activated by TGF-β promotes the invasion-metastasis cascade in hepatocellular carcinoma. Cancer Cell. 2014;25(5):666–81. doi:10.1016/j.ccr.2014.03.010.
16. Saito T, Kurashige J, Nambara S, Komatsu H, Hirata H, Ueda M, et al. A long non-coding RNA activated by transforming growth factor-β is an independent prognostic marker of gastric cancer. Ann Surg Oncol. 2015. doi:10.1245/s10434-015-4554-8.
17. Iguchi T, Uchi R, Nambara S, Saito T, Komatsu H, Hirata H, et al. A long noncoding RNA, lncRNA-ATB, is involved in the progression and prognosis of colorectal cancer. Anticancer Res. 2015;35(3):1385–8.
18. Qu S, Song W, Yang X, Wang J, Zhang R, Zhang Z, et al. Microarray expression profile of circular RNAs in human pancreatic ductal adenocarcinoma. Genomics Data. 2015;5:385–7.
19. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12(12):861–74. doi:10.1038/nrg3074.
20. Qu S, Yang X, Li X, Wang J, Gao Y, Shang R, et al. Circular RNA: a new star of noncoding RNAs. Cancer Lett. 2015;365(2):141–8. doi:10.1016/j.canlet.2015.06.003.
21. Kung JT, Colognori D, Lee JT. Long noncoding RNAs: past, present, and future. Genetics. 2013;193(3):651–69. doi:10.1534/genetics.112.146704.
22. Shi SJ, Wang LJ, Yu B, Li YH, Jin Y, Bai XZ. LncRNA-ATB promotes trastuzumab resistance and invasion-metastasis cascade in breast cancer. Oncotarget. 2015;6(13):11652–63.
23. Yang X, Wang J, Qu S, Zhang H, Ruan B, Gao Y, et al. MicroRNA-200a suppresses metastatic potential of side population cells in human hepatocellular carcinoma by decreasing ZEB2. Oncotarget. 2015;6(10):7918–29.
24. Lu R, Ji Z, Li X, Qin J, Cui G, Chen J, et al. Tumor suppressive microRNA-200a inhibits renal cell carcinoma development by directly targeting TGFB2. Tumour Biol. 2015 Mar 27. doi:10.1007/s13277-015-3355-9.
25. Xia H, Ng SS, Jiang S, Cheung WK, Sze J, Bian XW, et al. miR-200a-mediated down regulation of ZEB2 and CTNNB1 differentially inhibits nasopharyngeal carcinoma cell growth, migration and invasion. Biochem Biophys Res Commun. 2010;391(1):535–41. doi:10.1016/j.bbrc.2009.11.093.
26. Liu N, Zhong L, Zeng J, Zhang X, Yang Q, Liao D, et al. Up regulation of microRNA-200a associates with tumor proliferation, CSCs phenotype and chemosensitivity in ovarian cancer. Neoplasma. 2015;62(4):550–9. doi:10.4149/neo_2015_066.
27. Snowdon J, Zhang X, Childs T, Tron VA, Feilotter H. The microRNA-200 family is upregulated in endometrial carcinoma. PLoS One. 2011;6(8):e22828. doi:10.1371/journal.pone.0022828.
28. Li A, Omura N, Hong SM, Vincent A, Walter K, Griffith M, et al. Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. Cancer Res. 2010;70(13):5226–37.